As head of the section of Bioanalytical Chemistry, I oversee a talented and diverse team of experts responsible for the development and application of novel analytical methodology for global profiling and targeted analysis of small molecules, peptides, and beyond. Our principal application space is human biofluids and tissue extracts as well as the animal models and cell cultures needed to explore disease mechanisms in greater depth. Our favoured technology platforms include nuclear magnetic resonance (NMR), liquid chromatography mass spectrometry (LC-MS) and LC-tandem mass spectrometry (LC-MS/MS). We are most active in the areas of:
- Analytical method development
- Technology development and refinement
- Data extraction and pre-processing workflows
- Data quality control and monitoring
- Metabolite assignment and identification including structure elucidation
Together we work closely with clinicians, epidemiologists, and basic science researchers at Imperial to provide innovative and reliable solutions for metabolomics, lipidomics, and soon for proteomics.
As the Chief Operations Officer for the National Phenome Centre (NPC), I am responsible for operational management and delivery of a wide portfolio of research collaborations. Within the NPC, our focus is split between meeting the needs of high precision analysis demanded by large sample cohorts from molecular epidemiology studies, and those of studies involving smaller clinically derived cohorts analysed using both established and developing technologies.
et al., 2021, A Computationally Lightweight Algorithm for Deriving Reliable Metabolite Panel Measurements from 1D 1H NMR., Anal Chem, Vol:93, Pages:4995-5000
et al., 2021, Representing the metabolome with high fidelity: range and response as quality control factors in LC-MS-based global profiling., Analytical Chemistry, Vol:93, ISSN:0003-2700, Pages:1924-1933
et al., 2021, A targeted ultra performance liquid chromatography - Tandem mass spectrometric assay for tyrosine and metabolites in urine and plasma: Application to the effects of antibiotics on mice, Journal of Chromatography B-analytical Technologies in the Biomedical and Life Sciences, Vol:1164, ISSN:1570-0232
et al., 2021, Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid, Biomolecules, Vol:11
et al., 2021, Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer's disease, Alzheimers Research & Therapy, Vol:13, ISSN:1758-9193, Pages:1-18